0.05Open0.05Pre Close4 Volume87 Open Interest210.00Strike Price20.00Turnover2883.21%IV14.75%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0087Delta0.0014Gamma4925.40Leverage Ratio-86.6021Theta0.0000Rho-43.02Eff Leverage0.0001Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet